Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Helicobacter pylori (H. pylori) surface proteins and enzymes, along with the gastric mucosal surface, represent the complex biological interface where this Gram-negative bacterium colonizes the human stomach. Key bacterial components include the enzyme urease, which is essential for neutralizing gastric acid by producing ammonia, and various adhesins like Blood group antigen-binding adhesin (BabA) that facilitate attachment to the gastric epithelium [Mobley HL, et al., Microbiol Rev, 1995; Ishijima N, et al., J Biol Chem, 2011]. The gastric mucosal surface serves as the host environment, where the bacteria reside within or beneath the mucus layer to evade host immune responses and acid [StatPearls, Helicobacter Pylori, 2023]. This interface is the primary site of action for multi-drug regimens designed to eradicate the infection and treat associated pathologies [Malfertheiner P, et al., Gut, 2022]. Therapeutic strategies typically involve a combination of antibiotics, such as clarithromycin and amoxicillin, and proton pump inhibitors (PPIs) that modify the gastric environment to enhance drug stability and efficacy [Graham DY, et al., Gut, 2010]. This target complex is central to the pathogenesis of chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma [Polk DB, et al., Nat Rev Cancer, 2010]. Eradication of H. pylori from this mucosal interface is the gold standard for preventing disease recurrence and reducing cancer risk [Ford AC, et al., Cochrane Database Syst Rev, 2020]. Challenges in targeting this system include increasing antibiotic resistance and the protective nature of the gastric mucus layer [Thung I, et al., Aliment Pharmacol Ther, 2016].
Inhibition of bacterial cell wall synthesis, inhibition of bacterial protein synthesis, inhibition of bacterial DNA synthesis, inhibition of gastric acid secretion, and cytoprotective/antimicrobial effects.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Helicobacter pylori surface proteins and enzymes and gastric mucosal surface (H. pylori-gastric interface).